Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Swiss Nordic Bio

Läs om Swiss Nordic Bio

Corporate Finance

Vator Securities fokuserar på att identifiera och finansiera nordiska tillväxtbolag när de expanderar och utvecklas till morgondagens marknadsledare.

Läs mer

Analys

Vator Securities uppdragsanalys erbjuds till ett fåtal utvalda life science-bolag - ”By Invitation Only”. Uppdragsanalyser publiceras löpande under 2019.

Läs mer

Vator Securities Unicorn Summit arrangerades onsdagen den 27 november 2019 på IVA Konferenscenter i Stockholm och besöktes av över 200 deltagare.

Klicka här för att se presentationerna

BioWorks

Bio-Works Technologies – Leaving randomness

Bio-Works’s net sales for full year 2019 were SEK 5.6 million, down SEK 1 million from 2018. The decrease is due to the fact that the company’s largest customer in 2018 did not place an order in 2019.

In this update, we have looked beyond Bio-Works’s obvious stochastic character of the order inflow as we believe this is symptomatic for all early commercialization stage companies and not a structural problem for Bio-Works as such.

Läs mer

Swiss Nordic Bio 2020

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.

Läs mer

Vator Securities rådger SenzaGen i 106 MSEK riktad och företrädesemission

Den Riktade Emissionen tecknades av bland annat Fjärde AP-Fonden, Ålandsbanken Abp, Consensus Asset Management, Kavaljer, Segersta och Thomas Olausson.

Läs mer

AlzeCure Pharma – A win for the amyloid hypothesis is a win for AlzeCure

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

Läs mer

Fler nyheter